Avid Bioservices, Inc. (CDMO)

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that its wholly-owned subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO to execute manufacture of its ALA-002 drug substance. “PharmAla Australia worked diligently, executing a global RFP search to find our ideal partner for process development and manufacturing of the ALA-002 drug product components,” said Nick Kadysh, Founding CEO, PharmAla Biotech.

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025.

/PRNewswire/ -- Elevaris Medical Devices, l'organisation de développement et de fabrication sous contrat de classe mondiale résultant de l'acquisition de XL

/PRNewswire/ -- Elevaris Medical Devices, das Weltklasse-Auftragsunternehmen für Entwicklung und Herstellung, das aus der Übernahme des in Großbritannien

/PRNewswire/ -- Elevaris Medical Devices, the world-class Contract Development and Manufacturing Organization resulting from the acquisition of UK-based XL

/PRNewswire/ -- Elevaris Medical Devices, la organización de desarrollo y fabricación por contrato de clase mundial resultante de la adquisición de la

Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea , Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO). Following approval by its Board of Directors, Samsung Biologics separated its investment and subsidiary management business unit to establish Samsung Epis Holdings.

Partnership with "Saffron Tech" to Advance Production of One of the World's Most Valuable Botanicals Management Concurrently Shares Third Quarter 2025 Preliminary Results and Provides Guidance for the Fourth Quarter of 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced it has entered into a strategic CDMO agreement with Saffron Tech, a company pioneering advanced cultivation methods for saffron — one of the world's most valuable and health-promoting botanicals — to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform. Saffron CDMO Partnership Founded in 2020, Saffron Tech is a pioneer in revolutionizing saffron cultivation.

CINCINNATI--(BUSINESS WIRE)--National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced long-term debt financing of up to $825 million from Oak Hill Advisors (“OHA”) to strengthen its balance sheet and fuel its growth plans. This new capital will enable Resilience to accelerate its CDMO business strategy and invest in its go-forward manufacturing operations anchored in Cincinnati and Toronto. This financ.

Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad JERUSALEM , Oct. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA).

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea, has selected Thermo Fisher to provide advanced bioreactors and consumables for its newest facility. Dr. Park specializes in Adeno-associated virus-based (AAV-based) viral vector production and currently at 5,000 L per batch, producing up to 40 clinical-grade ba.

JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Results Highlights for Interim Results ended 30 June 2025 Revenue reached RMB831.9 million Gross profit amounted to RMB339.4 million Gross profit margin was 40.8%, an increase of 6.3 percentage point Net profit amounted to RMB148.6 million, increased by 3.1% YoY Adjusted non-IFRS net profit reached RMB183.5 million, increased by 9.1% YoY SHANGHAI , Aug. 28, 2025 /PRNewswire/ -- On August 28, 2025, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB831.9 million, and the Group's gross profit of RMB339.4 million. The Group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of Langhua's business structure, improved operational efficiency in CRO business, and contributions from new business segments.

SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO's Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP.

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been selected for the Ministry of Economy, Trade and Industry's “Regenerative CDMO Subsidy” as of July 15, 2025. The subsidy will support facility upgrades and equipment installation to expand biomanufacturing capacity for regenerative, cell, and gene therapies. Project Overview 1) Project Title JCR Rege.